

Bhatt Padmanabh P.
Form 4
May 14, 2018

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Bhatt Padmanabh P.

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS
PHARMACEUTICALS INC
[SUPN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director
 Officer (give title below)
____ 10% Owner
____ Other (specify below)
Sr. VP of IP, CSO

(Last) (First) (Middle)

3. Date of Earliest Transaction
(Month/Day/Year)
05/10/2018

C/O SUPERNUS
PHARMACEUTICALS, INC., 1550
EAST GUDE DRIVE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

ROCKVILLE, MD 20850

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price |
| Common Stock | 05/10/2018 | | M ⁽¹⁾ | | 20,000 | A | \$ 7.9 |
| | | | | | | | 32,500 |
| Common Stock | 05/10/2018 | | S ⁽¹⁾ | | 20,000 | D | \$ 49.8772 |
| | | | | | | | 12,500 |
| Common Stock | 05/11/2018 | | M ⁽¹⁾ | | 20,000 | A | \$ 7.9 |
| | | | | | | | 32,500 |
| Common Stock | 05/11/2018 | | S ⁽¹⁾ | | 20,000 | D | \$ |
| | | | | | | | 12,500 |

Edgar Filing: Bhatt Padmanabh P. - Form 4

| | | | | | | | | |
|--------------|------------|--|--------------|--------|---|------------------------------------|--------|---|
| Stock | | | | | | 52.0279 <u>(3)</u> | | |
| Common Stock | 05/11/2018 | | <u>M</u> (1) | 11,250 | A | \$ 9.24 | 23,750 | D |
| Common Stock | 05/11/2018 | | <u>S</u> (1) | 16,250 | D | \$ <u>55.2334</u> <u>(4)</u> | 7,500 | D |
| Common Stock | 05/11/2018 | | <u>M</u> (1) | 10,882 | A | \$ 9.24 | 18,382 | D |
| Common Stock | 05/11/2018 | | <u>S</u> (1) | 10,882 | D | \$ 57.9 | 7,500 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | | |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--------------|----------------------------|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Employee Stock Option (Right to Buy) | \$ 7.9 | 05/10/2018 | | <u>M</u> (1) | 20,000 | <u>(5)</u> | 02/05/2023 | Common Stock | 20,000 |
| Employee Stock Option (Right to Buy) | \$ 7.9 | 05/11/2018 | | <u>M</u> (1) | 20,000 | <u>(5)</u> | 02/05/2023 | Common Stock | 20,000 |
| Employee Stock Option (Right to Buy) | \$ 9.24 | 05/11/2018 | | <u>M</u> (1) | 11,250 | <u>(6)</u> | 01/21/2024 | Common Stock | 11,250 |

| | | | | | | | | |
|--|---------|------------|------------------|--------|------------|------------|-----------------|--------|
| Employee Stock Option (Right to Buy) | \$ 9.24 | 05/11/2018 | M ⁽¹⁾ | 10,882 | <u>(6)</u> | 01/21/2024 | Common Stock | 10,882 |
|--|---------|------------|------------------|--------|------------|------------|-----------------|--------|

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|-------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Bhatt Padmanabh P. C/O SUPERNUS PHARMACEUTICALS, INC. 1550 EAST GUDE DRIVE ROCKVILLE, MD 20850 | | | Sr. VP of IP, CSO | |

Signatures

/s/ Gregory S. Patrick, as
attorney-in-fact

05/14/2018

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017.

(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$49.8500 to \$49.9500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$51.8500 to \$52.2750, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

(4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$54.8500 to \$55.5000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

(5) The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted.

(6) The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.